• Early Bird
  • Posts
  • Gilead's HIV Therapy Business đź’Š

Gilead's HIV Therapy Business đź’Š

And, TRON's potential Solana dreams.

March 19, 2025

In partnership with

Today is Wednesday, March 19, 2025.

The Early Bird Index today is 68.51

New to this newsletter? Sign up here

Gilead's HIV Therapy Business đź’Š

Biopharmaceutical company Gilead Sciences $GILD ( â–Ľ 0.22% ) fell 2.97% in after-hours trading on Tuesday after a report suggested a potential problem for its burgeoning HIV therapy business.

Details: The Wall Street Journal reported on Tuesday that the Trump administration is considering a plan to drastically cut the federal government’s funding for domestic HIV prevention. The plan could be announced in the coming days.

Background: HIV treatment accounts for 63% of Gilead’s revenue.

Zooming Out: Gilead’s HIV treatments are a big reason why the stock surged in 2024.

Early Bird’s Nest Egg Gains: If the cuts occur, Gilead would face mixed financial and operational impacts.

  • Federal funding cuts could decrease government procurement of Gilead’s HIV prevention drugs for programs such as Medicaid. 

  • However, Gilead’s revenue reliance on HIV therapies is partially insulated because treatment demand often remains stable or sometimes increases.

Final Thoughts: GlaxoSmithKline $GSK ( â–˛ 1.27% ) , which also produces HIV drugs, dipped 0.45% in after-hours trading.

Big Tech Has Spent Billions Acquiring AI Smart Home Startups

The pattern is clear: when innovative companies successfully integrate AI into everyday products, tech giants pay billions to acquire them.

Google paid $3.2B for Nest.
Amazon spent $1.2B on Ring.
Generac spent $770M on EcoBee.

Now, a new AI-powered smart home company is following their exact path to acquisition—but is still available to everyday investors at just $1.90 per share.

With proprietary technology that connects window coverings to all major AI ecosystems, this startup has achieved what big tech wants most: seamless AI integration into daily home life.

Over 10 patents, 200% year-over-year growth, and a forecast to 5x revenue this year — this company is moving fast to seize the smart home opportunity.

The acquisition pattern is predictable. The opportunity to get in before it happens is not.

Past performance is not indicative of future results. Email may contain forward-looking statements. See US Offering for details. Informational purposes only.

Notables

Notable Earnings Today: Signet Jewelers (NYSE: SIG), Five Below (Nasdaq: FIVE), General Mills (NYSE: GIS), Williams-Sonoma (NYSE: WSM), Kingsoft Cloud (Nasdaq: KC), Sportradar Group (Nasdaq: SRAD), Ollie's Bargain Outlet (Nasdaq: OLLI), JOYY (Nasdaq: YY), Worthington Steel (NYSE: WS), Aeva (Nasdaq: AEVA), Capricor Therapeutics (Nasdaq: CAPR), FrontView REIT (NYSE: FVR), HUTCHMED (Nasdaq: HCM), J. Jill (NYSE: Jill), MediWound (Nasdaq: MDWD), MSC Income Fund (NYSE: MSIF).

Notable IPOs Today: Baiya International Group Inc. Ordinary Shares (Nasdaq: BIYA).

Notable Equity Crowdfunding Campaigns Ending Today: Aerovec (StartEngine), Bracketology (Wefunder), The Axe Parlor (Honeycomb), VQ Research (StartEngine).

Notable Economic Events Today: Crude Oil Inventories (9:30 a.m. ET), Fed Interest Rate Decision / FOMC Statement (2:00 p.m. ET), TIC Net Long-Term Transactions (4:00 p.m. ET).

TRON's Potential Solana Dreams

The price of the cryptocurrency TRON $TRX.X ( â–Ľ 0.84% ) jumped about 9% on Tuesday thanks to the excitement from a new potential partnership.

Details: Justin Sun, founder of the TRON blockchain, wrote on X on Tuesday that TRON will soon join the Solana $SOL.X ( â–˛ 2.21% ) Network.

Background: TRON’s price peaked in December 2024 but has since fallen. Even with the exciting announcement on Tuesday, TRON’s price is still down 5% in 2025.

Final Thoughts: Further details about this potential integration are still unknown at this time.

HealthEquity Slides Due to Mixed Results

The health savings account company HealthEquity $HQY ( â–Ľ 0.29% ) declined by 13.46% in after-hours trading on Tuesday after posting mixed financial results.

Financials: HealthEquity reported earnings of 69 cents per share in the past quarter, which was lower than expected. The company’s revenue was $311.8 million, which was better than expected.

Final Thoughts: The stock was already down 10% in the last 30 days.

Auto-Proxy Fight: Starboard plans to launch proxy fight at Autodesk (Wall Street Journal)

Thank you for reading!

Forward to a friend and tell them to sign up here.

Want more investing tips? Listen to the podcast.

Show Your Support: Buy Me a Coffee.

Questions or comments? Hit reply to reach out.

The contents of Early Bird are intended for informational and entertainment purposes only. They do not constitute trade or investment recommendations and they are not financial or legal advice. Readers are encouraged to consult licensed professionals for personalized guidance regarding their financial or legal situations.